Bloodstream infections in patients living with HIV in the modern cART era.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 04 2019
Historique:
received: 31 07 2018
accepted: 14 03 2019
entrez: 2 4 2019
pubmed: 2 4 2019
medline: 6 10 2020
Statut: epublish

Résumé

Retrospective multicentre study aiming at analysing the etiology, characteristics and outcome of bloodstream infections (BSI) in people living with HIV (PLWHIV) in an era of modern antiretroviral therapy. Between 2008 and 2015, 79 PLWHIV had at least 1 BSI, for a total of 119 pathogens isolated. Patients were mainly male (72.1%), previous intravenous drug users (55.7%), co-infected with HCV or HBV (58.2%) and in CDC stage C (60.8%). Gram-positive (G+) pathogens caused 44.5% of BSI, followed by Gram-negative (G-), 40.3%, fungi, 10.9%, and mycobacteria, 4.2%. Candida spp. and coagulase-negative staphylococci were the most frequent pathogens found in nosocomial BSI (17% each), while E.coli was prevalent in community-acquired BSI (25%). At the last available follow-up, (mean 3.2 ± 2.7 years) the overall crude mortality was 40.5%. Factors associated with mortality in the final multivariate analysis were older age, (p = 0.02; HR 3.8, 95%CI 1.2-11.7) CDC stage C (p = 0.02; HR 3.3, 95%CI 1.2-9.1), malignancies, (p = 0.004; HR 3.2, 95%CI 1.4-7.0) and end stage liver disease (p = 0.006; HR 3.4, 95%CI 1.4-8.0). In conclusion, the study found high mortality following BSI in PLWHIV. Older age, neoplastic comorbidities, end stage liver disease and advanced HIV stage were the main factors correlated to mortality.

Identifiants

pubmed: 30931978
doi: 10.1038/s41598-019-41829-3
pii: 10.1038/s41598-019-41829-3
pmc: PMC6443940
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

5418

Références

Lancet HIV. 2018 Apr;5(4):e172-e180
pubmed: 29352723
Infect Control Hosp Epidemiol. 1997 Jul;18(7):479-85
pubmed: 9247830
Clin Infect Dis. 2002 Mar 1;34(5):677-85
pubmed: 11823956
AIDS. 1999 Apr 1;13(5):599-605
pubmed: 10203385
Med 2 0. 2013 Aug 13;2(2):e5
pubmed: 25075240
Lancet HIV. 2017 Mar;4(3):e105-e112
pubmed: 28063815
J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):951-9
pubmed: 15220702
Diagn Microbiol Infect Dis. 2007 Jul;58(3):325-31
pubmed: 17350205
Clin Infect Dis. 2009 Jan 1;48(1):1-12
pubmed: 19035777
Trop Med Int Health. 2013 Apr;18(4):485-94
pubmed: 23294446
Int J Infect Dis. 2007 May;11(3):226-31
pubmed: 16815065
J Infect Dis. 2000 Apr;181(4):1414-20
pubmed: 10762572
BMC Infect Dis. 2017 Feb 2;17(1):116
pubmed: 28148226
AIDS. 2015 Oct 23;29(16):2099-108
pubmed: 26544576
Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):969-76
pubmed: 18449581
Int J Infect Dis. 2002 Mar;6(1):17-22
pubmed: 12044296
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
Clin Infect Dis. 2007 Feb 1;44(3):441-6
pubmed: 17205456
Semin Nucl Med. 1978 Oct;8(4):283-98
pubmed: 112681
AIDS. 1996 Dec;10(14):1635-9
pubmed: 8970683
J Infect Prev. 2014 Nov 1;15(6):214-220
pubmed: 25484924
Clin Infect Dis. 1998 Feb;26(2):290-6
pubmed: 9502444
Clin Infect Dis. 2008 Mar 15;46(6):787-94
pubmed: 18266611
Int J Infect Dis. 2001;5(2):63-9
pubmed: 11468099
Virulence. 2016 Apr 2;7(3):320-8
pubmed: 26950194
Lancet HIV. 2015 Oct;2(10):e438-44
pubmed: 26423651
BMC Infect Dis. 2001;1:13
pubmed: 11602019
BMC Infect Dis. 2015 Oct 13;15:415
pubmed: 26464061
PLoS One. 2014 Jul 30;9(7):e102671
pubmed: 25076050
J Infect. 2013 May;66(5):439-46
pubmed: 23353671
AIDS. 2002 Feb 15;16(3):359-67
pubmed: 11834947
J Acquir Immune Defic Syndr. 2000 Feb 1;23(2):145-51
pubmed: 10737429
J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):407-15
pubmed: 19474755
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
J Healthc Eng. 2017;2017:2190679
pubmed: 29065576
AIDS. 2008 Nov 30;22(18):2461-9
pubmed: 19005269
Clin Infect Dis. 2011 Feb 1;52(3):341-8
pubmed: 21217181
HIV Med. 2007 Nov;8(8):547-54
pubmed: 17944688
HIV Med. 2011 Jan;12(1):61-4
pubmed: 20561080

Auteurs

L Taramasso (L)

University of Genova (DISSAL), Infectious Diseases Clinic, Policlinico Hospital San Martino, Genova, Italy. taramasso.lucia@gmail.com.
Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. taramasso.lucia@gmail.com.

F Liggieri (F)

University of Genova (DISSAL), Infectious Diseases Clinic, Policlinico Hospital San Martino, Genova, Italy.

G Cenderello (G)

Infectious Diseases Unit, EO Ospedali Galliera, Genova, Italy.

F Bovis (F)

Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy.

B Giannini (B)

Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genova, Genova, Italy.

A Mesini (A)

University of Genova (DISSAL), Infectious Diseases Clinic, Policlinico Hospital San Martino, Genova, Italy.

M Giacomini (M)

Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genova, Genova, Italy.

G Cassola (G)

Infectious Diseases Unit, EO Ospedali Galliera, Genova, Italy.

C Viscoli (C)

University of Genova (DISSAL), Infectious Diseases Clinic, Policlinico Hospital San Martino, Genova, Italy.

A Di Biagio (A)

Infectious Diseases Clinic, Policlinico Hospital San Martino, Genova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH